Teicoplanin (Synonyms: Antibiotic 8327A, Antibiotic MDL 507, MDL 507) |
Catalog No.GC11339
One-Click Copy Product Info
|
Teicoplanin is a glycopeptide antibiotic of the vancomycin class obtained from fermentation by Actinoplanes teichomyceticus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61036-62-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Teicoplanin is a glycopeptide antibiotic of the vancomycin class obtained from fermentation by Actinoplanes teichomyceticus. Teicoplanin binds to the D-Ala-D-Ala terminus of peptidoglycan precursors to block cell wall cross-linking and inhibit cell wall synthesis of Gram-positive bacteria, and enhances antibacterial effects through its hydrophobic side chain interfering with lipid II and cell membrane permeability. Teicoplanin can be used in research on infective endocarditis, osteomyelitis, septicemia caused by drug-resistant Gram-positive bacteria such as MRSA, and Clostridium difficile-associated diarrhea[1-4].
In vitro, Teicoplanin (1nM-100μM) treated Vero cells infected with EBOV Zaire GP/HIV core pseudovirus for 72h. Teicoplanin dose-dependently inhibited pEBOV infection with CC50>125μM[5]. Teicoplanin (130, 520, 890μg/mL) treated MCF-7 human breast cancer cells for 68h. Teicoplanin downregulated the mRNA expression of c-myc and c-fos in cells[6].
In vivo, Teicoplanin (1-120mg/kg; 4, 6, 8, 12, 24h intervals; 5 doses total) was intravenously administered 2h post-inoculation to cyclophosphamide-induced neutropenic mice with thigh Staphylococcus aureus infection (MSSA ATCC 29213 or MRSA ATCC 43300) for 24h treatment. Teicoplanin inhibited S. aureus burden growth in mouse thigh tissues[7]. Teicoplanin (100, 200, 500μg; single injection) was intracerebroventricularly injected (4μL/mouse; within 4min) into male ICR mice (5-6 weeks old; 25-30g). Teicoplanin induced behavioral seizures such as head twitching and forelimb clonus, accompanied by high-voltage polyspike waves in frontal cortex, hippocampus and amygdala[8].
References:
[1] Shea KW, Cunha BA. Teicoplanin. Med Clin North Am. 1995 Jul;79(4):833-44. doi: 10.1016/s0025-7125(16)30042-6.
[2] Parenti F, Schito GC, Courvalin P. Teicoplanin Chemistry and Microbiology. J Chemother. 2000 Nov;12 Suppl 5:5-14.
[3] Yushchuk O, Ostash B, Truman AW, et al. Teicoplanin biosynthesis: unraveling the interplay of structural, regulatory, and resistance genes. Appl Microbiol Biotechnol. 2020 Apr;104(8):3279-3291.
[4] Greenwood D. Microbiological properties of teicoplanin. J Antimicrob Chemother. 1988 Jan;21 Suppl A:1-13.
[5] Wang Y, Cui R, Li G, et al. Teicoplanin inhibits Ebola pseudovirus infection in cell culture. Antiviral Res. 2016 Jan;125:1-7.
[6] Ashouri S, Khujin MH, Kazemi M, et al. Effect of teicoplanin on the expression of c-myc and c-fos proto-oncogenes in MCF-7 breast cancer cell line. Adv Biomed Res. 2016 Nov 28;5:172.
[7] Watanabe E, Matsumoto K, Ikawa K, et al. Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model. J Glob Antimicrob Resist. 2021 Mar;24:83-87.
[8] Takechi K, Ishikawa T, Kamei C. Epileptogenic activity induced by teicoplanin and effects of some antiepileptics in mice. J Pharmacol Sci. 2008 Aug;107(4):428-33.
| Cell experiment [1]: | |
Cell lines | MCF-7 cells (human breast cancer cell line) |
Preparation Method | MCF-7 cells were maintained in RPMI-1640 medium supplemented with 100 units/mL penicillin G, 100μg/mL streptomycin and 10% fetal bovine serum at 37°C, 5% CO₂. MCF-7 cells were treated with Teicoplanin at 130, 520 and 890μg/mL for 68h, then harvested for MTT assay and real-time PCR to detect mRNA expression of c-myc and c-fos (normalized to GAPDH). |
Reaction Conditions | 130, 520, 890μg/mL; 68h |
Applications | Teicoplanin treatment led to significant difference in MCF-7 cell proliferation rate compared with control groups. Teicoplanin significantly downregulated mRNA expression of c-myc and c-fos in MCF-7 cells at all three tested concentrations; the downregulation amplitude of c-myc at 890μg/mL was significantly lower than that at 130 and 520μg/mL, and the downregulation amplitude of c-fos at 520μg/mL was significantly stronger than that at 130μg/mL. |
| Animal experiment [2]: | |
Animal models | Neutropenic male ddY mice (5-week-old); thigh infection models were established by inoculating methicillin-susceptible Staphylococcus aureus (MSSA) ATCC 29213 or methicillin-resistant S. aureus (MRSA) ATCC 43300 |
Preparation Method | 5-week-old male ddY mice were rendered neutropenic via intraperitoneal cyclophosphamide administration at 150mg/kg 4 days prior to infection and 100mg/kg 1 day prior to infection. For thigh infection model, 100μL early-log-phase S. aureus suspension (3.75×10⁶ CFU/mL) was intramuscularly injected into one posterior thigh muscle. Teicoplanin was administered intravenously 2h post-inoculation, with dosing regimens covering 1-120mg/kg at 4-, 6-, 8-, 12-, 24-h intervals (5 dose in total), mice were sacrificed 24h after initial dosing for thigh bacterial load enumeration via CFU counting. |
Dosage form | 1-120mg/kg; i.v.; 4/6/8/12/24h intervals; 5 dose in total |
Applications | Teicoplanin dose-dependently inhibited S. aureus thigh burden growth in neutropenic mice. |
References: | |
| Cas No. | 61036-62-2 | SDF | |
| Synonyms | Antibiotic 8327A, Antibiotic MDL 507, MDL 507 | ||
| Formula | C77H77N9O31Cl2·R | M.Wt | 1564.3-1907.7 |
| Solubility | DMSO: 0.15 mg/ml,PBS (pH 7.2): 0.25 mg/ml | Storage | Store at 2-8°C,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 639.3 μL | 3.1963 mL | 6.3926 mL |
| 5 mM | 127.9 μL | 639.3 μL | 1.2785 mL |
| 10 mM | 63.9 μL | 319.6 μL | 639.3 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Potency: >900ug/mg
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 23 reference(s) in Google Scholar.)